References
- Armbruster DA, Pry T. (2008). Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29:S49–52
- Bauer DC, Hunter DJ, Abramson SB, et al. (2006). Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14:723–7
- Baumgartner C, Osl M, Netzer M, Baumgartner D. (2011). Bioinformatic-driven search for metabolic biomarkers in disease. J Clin Bioinform 1:2. doi: 10.1186/2043-9113-1-2
- Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
- Birmingham JD, Vilim V, Kraus VB. (2007). Collagen biomarkers for arthritis applications. Biomark Insights 1:61–76
- Deberg M, Dubuc JE, Labasse A, et al. (2008). One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 67:168–74
- Deberg M, Labasse A, Christgau S, et al. (2005). New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13:258–65
- FDA, USDOHAHS, CDER, CVM. (2013). Guidance for industry: bioanalytical method validation. Revision 1 ed. Silver Spring (MD): Food and Drug Administration
- Fleming TR, Powers JH. (2012). Biomarkers and surrogate endpoints in clinical trials. Stat Med 31:2973–84
- Gharbi M, Deberg M, Henrotin Y. (2011). Application for proteomic techniques in studying osteoarthritis: a review. Front Physiol 2:90. doi: 10.3389/fphys.2011.00090
- Henrotin Y, Addison S, Kraus V, Deberg M. (2007). Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 19:444–50
- Henrotin Y, Gharbi M, Mazzucchelli G, et al. (2012). Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis Rheum 64:2260–7
- Hsueh MF, Onnerfjord P, Kraus VB. (2014). Biomarkers and proteomic analysis of osteoarthritis. Matrix Biol 39:56–66
- Karsdal MA, Christiansen C, Ladel C, et al. (2014). Osteoarthritis – a case for personalized health care? Osteoarthritis Cartilage 22:7–16
- Kraus VB. (2012). Patient evaluation and OA study design: OARSI/biomarker qualification. HSS J 8:64–5
- Kraus VB, Blanco FJ, Englund M, et al. (2015). OARSI Clinical Trials Recommendations: soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 23:686–97
- Kraus VB, Burnett B, Coindreau J, et al. (2011). Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 19:515–42
- Lohmander LS, Dahlberg L, Ryd L, Heinegard D. (1989). Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 32:1434–42
- Lohmander LS, Saxne T, Heinegard DK. (1994). Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 53:8–13
- Lotz M, Martel-Pelletier J, Christiansen C, et al. (2013). Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 72:1756–63
- Mahjoub M, Berenbaum F, Houard X. (2012). Why subchondral bone in osteoarthritis? The importance of the cartilage bone interface in osteoarthritis. Osteoporos Int 23:S841–6
- Man GS, Mologhianu G. (2014). Osteoarthritis pathogenesis – a complex process that involves the entire joint. J Med Life 7:37–41
- Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. (2004). The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 294:145–53
- Schalken JA. (2010). Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 58:19–20
- van Spil WE, Degroot J, Lems WF, et al. (2010). Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil 18:605–12
- Wagner JA, Williams SA, Webster CJ. (2007). Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81:104–7